[ad_1]
For its course National Vaccine Coverage Plan Against him coronavirus The president of the National Vaccination Committee spoke on Monday afternoon. Maria Theodoridou and the Secretary General of Primary Health Care Marios Themistocleous.
For AstraZeneca vaccine and thrombosis cases
For his part, Maria Theodoridou mentioned in the context of the preventive suspension of vaccines in several EU countries with the AstraZeneca vaccine.
He stressed that Greece agreed with the decisions of E.European Medicines Agency (EMA), continuing the vaccination process normally with this vaccine.
As Ms Theodoridou said, “There is still insufficient evidence to show that the vaccine is completely associated with cases of thrombosis or with the rare reported phenomenon of thrombosis and diffuse vascular coagulation.
All Covid 19 vaccines protect against the coronavirus, but not against other diseases. Conditions that lead to death should not be associated with the vaccine.
The International Society for Thrombosis and Haemostasis strongly recommends vaccination even for people taking blood thinners or blood thinners.
Tips for Low Vaccination Rates for Doctors and Nurses
However, Ms Theodoridou’s report on the issue of Covid 19 hospital spread caused a sensation.
“The cases of hospital dispersion worry us a lot. We know that the percentages of healthcare workers who are vaccinated could be much better, but we hope this will change, ”said Ms Theodoridou.
As he said, “there are cases in which people are vaccinated even after the administration of both doses of the vaccine, but these in percentage do not exceed 0.2%. However, such a thing should not be raised as an excuse, not to carry out vaccines ”.
Themistocleous: Opening of the dating platform for Vaccination Group A
For his part, the Secretary General for Primary Health Care, Marios Themistokleous, presented the data on the evolution of vaccinations in our country.
As he said:
- 29,000 vaccinations were carried out on Monday – 1,464,000 vaccinations were carried out within the framework of Operation Freedom
- 993,000 of our fellow citizens have already received a dose of vaccine (9.74%)
- 415,000 of our fellow citizens have been vaccinated with both doses
Since Friday, more than 100,000 appointments have been made for people with very high-risk diseases (Vaccination Group A).
“The vaccination rate is accelerating based on the availability of vaccines,” repeated Themistokleous.
For catering and tourism, pointed that after vaccination of Group B in May, but also of teachers There will be planning if they will be vaccinated and specific professional groups.
Information on prioritizing patients with high-risk diseases
According to emvolio.gov.gr, the prioritization of this population group includes patients suffering from the diseases described in the following table (table 1) as well as those receiving medication in table 2.
See the presentation in detail here.
Table 1
|
High risk diseases |
ICD 10 |
|
|
Transplant |
|
Z94, T86 |
|
Renal insufficiency |
|
N18, N19, Y84.1 |
|
E84 |
|
|
Cancer in treatment |
|
C00 to 97 (excluding hematologic cancer) D37 to D48 C81 to C86, C88 C90 to C95 |
|
Serious chronic respiratory diseases |
|
J44 J84 |
|
Severe heart disease |
|
I21 to I23 fifty I27, I28 |
|
Severe liver disease |
|
K72, K72.1, K72.9, K76.6, K74, K74.4, K74.5, K74.6, K70.3, K70.4 |
|
Immunosuppression |
|
D80-D84 |
|
Other diseases |
|
Q90 |
- *People in cancer treatment since 1/1/2019
- **People who have been diagnosed with hematologic cancer since 1/1/2016
- *** People with a diagnosis of acute myocardial infarction since 12/1/2020
- **** Includes patients with idiopathic inflammatory diseases of the gastrointestinal tract (idiopathic inflammatory bowel disease), liver (autoimmune hepatitis), skin (psoriasis, blistering skin diseases), renal lupus erythematosus (primary or subclinical), vasculitis, myositis, scleroderma, S. Sjögren , etc.) or other disease, who are receiving the drug in Table 2.
Table 2
|
Immunosuppressive / immunomodulatory treatment Moderate – high risk |
|
|
ATC code |
|
|
Glucocorticoids |
|
|
Prednisolone, methylprednisolone (pos / IV) * |
H02AB06, H02AB04 |
|
Non-biological agents |
|
|
Azathioprine (AZA) |
L04AX01 |
|
Cyclophosphamide (CYC) |
L01AA01 |
|
Cyclosporine (CsA) |
L04AD01 |
|
Leflunomide (LEF) |
L04AA13 |
|
Methotrexate (MTX) |
L04AX03 |
|
6-mercaptopurine (6-MP) |
L01BB02 |
|
Mycophenolate acid (MPA) |
L04AA06 |
|
Mycophenolate mofetil (MMF) |
L04AA06 |
|
Tacrolimus |
L04AD02 |
|
Biological factors |
|
|
Abatacept |
L04AA24 |
|
Anti-IL1 (Anakinra, Canakinumab) |
L04AC03, L04AC08 |
|
Anti-IL6 (tocilizumab) |
L04AC07 |
|
Anti-IL12 / 23 (Ustekinumab) |
L04AC05 |
|
Anti-IL17 (Brodalumab, Secukinumab) |
L04AC12, L04AC10 |
|
Anti-TNF (Adalimumab, Certolizumab pegol, Etanercept, Golimumab, Infliximab) |
L04AB04, L04AB05, L04AB01, L04AB06, L04AB02 |
|
Belimumab |
L04AA26 |
|
Αanti-B cell (rituximab) |
L01XC02 |
|
Targeted synthetic agents |
|
|
Apremilast |
L04AA32 |
|
JAK inhibitors (tofacitinib) |
L04AA29 |
* Prednisolone> 20 mg daily for> 30 days or 700 mg total dose for 2 months.
The correspondence of the most used steroids is as follows:
- Prednisolone 5 mg
- Methylprednisolone 4 mg
- Dexamethasone 0.75 mg
- Hydrocortisone 20 mg
- Betamethasone 0.6 mg per week
